Functional HIV Cure Found In Monkeys? Surprising Studies Show; Details Inside
American immunologist Dr. Anthony Fauci doesn't usually get too excited about the results of animal studies, and he doesn't make house calls. However, recently, it was found that the attention of the director of the National Institutes of Allergy and Infectious Diseases has been caught when a drug that has already been taken by thousands of people for intestinal conditions has seemingly appeared to control the monkey version of HIV.
Monkeys: Could They Be The Key For HIV Cure?
According to Daily Mail, it was found that the director of the National Institutes of Allergy and Infectious Diseases has personally praise Japan's Takeda Pharmaceutical Co's U.S. representatives that their drug may offer a dramatic advance in the fight against AIDS. Takeda's innovative drug has allegedly suppressed the virus to undetectable levels in eight monkeys, some for two years.
Experts say that the drug is one of several promising ideas which is heading into early-stage human trials, all of which are known to be seeking to help patients control the virus that causes AIDS for extended periods without daily antiretroviral therapy (ART). Executive director of the AIDS Vaccine Advocacy Coalition adds that there has been this explosion of discovery as it has been previously been perceived as something that's impossible to conceive.
Furthermore, The Daily Star reports that if ART would be taken on a daily basis, it is more likely to suppress the virus. But keeping up a daily medication regimen is difficult. The drugs are expensive and toxic, causing nausea, fatigue and nerve problems in the short term, and insulin resistance and other problems over time. Dr. Nelson Michael, director of the U.S. Military HIV Research Program at the Walter Reed Army Institute has claimed that on its own, the vaccine had a modest effect and could potentially become even more effective when it was given with GS-986, a so-called TLR-7 agonist that has the ability to kick the immune system up to a higher gear.
Ultimately, Dr. Paul Stoffels, J&J's chief scientific officer has revealed that they are set to conduct human trials within months. He adds that if the cure is there, the industry will find a way to get there very quickly.
Mother’s Allergy During Pregnancy Linked To Autism And ADHD?
With The Persistence Of Allergies, Can A Mother’s Allergy Cause Adverse Health Problems Than The Usual? Are There Underlying Health Effects Of It?
Not A Fan of Fruits And Vegetables? Study Says You Are At Risk Of Having Asthma. Here’s Why
Study Finds That The Lack Of Fruit And Vegetable Consumption Can Actually Trigger Asthma And Other Respiratory Diseases, Find Out Why
Living In U.S. Raises Risk Of Allergies
Children born outside of the U.S. have a lower rate of asthma, food and skin allergies.
[Japanese Simulation] The Next Mt. Fuji Volcano Eruption Could Leave Tokyo With 10 Times The Debris Compared to 2011 Tsunami
The Japanese government has decided to release a simulation to warn the people to prepare themselves adequately should Mt. Fuji Volcano erupt in the possibly near future.
Robot Wars: China's MegaBot Challenger Wants To Fight In World's First Robot Battle
China may join in the upcoming robot wars, challenging giant fighting robots made by USA and Japan. Dubbed the Monkey King, the latest megabot challenger may kick off a robot fighting league.
MORE IN ITECHPOST
Never Before Seen Beauty of Himalayas in the Last 30 Years Captured By The Lens, Thanks To Coronavirus Lockdown!
Different social media sites were filled with some delightful images as more and more residents laid eyes on the entire Himalayan range
NASA Spotted Record-Breaking 1 Million Square Kilometer Rare Hole Above Arctic
The rare hole has opened up in the ozone layer above the Arctic which is set to be the largest of its kind ever detected.
Valorant Won't Kill Fortnite: Tfue Explains Why
A certain twitch streamer by the name of Tfue has just recently tried out Riot Games' Valorant explaining to his followers that the games do not cater to the same audiences.